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Discussion

Introduction

Pulmonary emboli are a serious life-threatening diagnosis that physicians
never want to miss. Due to the common and non-specific nature of
symptoms associated with pulmonary emboli, risk stratification tools
have been developed and widely implemented to improve diagnostic
accuracy while limiting unnecessary imaging. As our knowledge of
molecular medicine increases the question arises of previously unknown
risk factors which are not included in traditional risk calculators.

Pulmonary emboli are serious, life-threatening events and their diagnosis can
be complicated by the presence of other significant pulmonary pathology.
When patients do not respond to initial medical treatment as expected it is
always important to reevaluate and reconsider other possible etiologies of
complaints (avoiding anchoring bias and premature closure). With pulmonary
complaints, it is pertinent to keep in mind that the presence of a pulmonary
infection does not exclude a thrombotic event.

Case Description
History
A 54 yo male with a history of tobacco use presented to the ED with one week of
malaise, nonproductive cough and two days of shortness of breath, pleuritic chest
pain and headaches. He denied any other past medical history and had not been
smoking since he became ill.
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Pertinent Physical Exam Findings
T: 37.6, HR: 92, BP 126/77, RR: 24, O2sat: 92% on 15 L via nonrebreather
His initial physical exam was unremarkable, including a clear lung exam

Another case study chronicled the clinical course of a hypertensive 28
year old male found to have pulmonary emboli and serologies positive
for mycoplasma pneumoniae. In his case he had positive lupus
anticoagulant and anticardiolipin antibodies but there was not mention of
follow-up antibodies tests returning to normal.

Pertinent Laboratory Findings
WBC 13.6 with 83% neutrophils and a left shift
Total protein 8.5 (6.1-8.2 g/dL), albumin 2.7 (3.4-4.7 g/dL), AST 108 (6-58 units/L),
ALT 152 (14-67 units/L), Alkaline phosphatase 176 (38-150 units/L),
total bilirubin 1.5 (0.3-1.2 mg/dL), direct bilirubin 0.5 (0.1-0.4 mg/dL)
CK 563 (37-242 units/L), Troponin normal x 2
Influenza PCR was negative
Imaging
Chest xray showed a left lower lobe bronchial infiltrate consistent with a pneumonia
vs aspiration

CXR 2

Hospital Course
*Patient was admitted to the hospital and started on community acquired pneumonia
treatment with azithromycin and ceftriaxone.
*On hospital day 4 he had no improvement so a CT-Chest without contrast was
performed which showed extensive inflammatory bronchiolitis that favored a viral or
atypical pneumonia, thus more serologies including mycoplasma pneumoniae,
coccidioidimycosis and histoplasmosis were ordered
*On hospital day 7 he continued to have profound hypoxia and a CT-Chest
Angiogram was performed which revealed multiple segmental pulmonary emboli in
his right lower lobe.
*He was switched from prophylactic anticoagulation to therapeutic anticoagulation
and the next day his mycoplasma IgG and IgM both came back positive
*He was treated with 14 days of azithromycin and discharged on oxygen and a three
month prednisone taper as recommended by Pulmonology

Mycoplasma pneumoniae infections have been linked to thromboemboli
in children (a normally very low risk population) in several case studies
over the years. In all the reported cases children were otherwise healthy
admitted with respiratory distress and found to have IgG and IgM
antibodies to mycoplasma pneumoniae as well as a documented
thromboembolism in the form of either a DVT, pulmonary embolism,
cardiac thrombus or cerebral venous thrombosis. In 5 of the 6 cases
children had positive prothrombic markers (such as antiphospholipid
antibodies) during the acute phase that resolved with treatment of
infection. In the 6th case the child was found to have a familial
antithrombin deficiency.
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In our patient’s case he did not have other risk factors for thromboemboli
and using traditional methods of risk stratification, such as Well’s criteria,
he would have been low probability. This case demonstrates the
importance of reevaluating diagnoses when a patient is not responding to
treatment as expected. It also demonstrates that there are common
conditions associated with the development of prothrombotic factors
which are not accounted for in current risk stratification models.

Conclusion
*Risk stratification tools for pulmonary emboli should be used but
providers should consider whether there is a prothrombotic condition
that is not accounted for in the model.
*More investigations into infections as risk factors for thromboemboli
are needed.
*Physicians should be aware of the association of mycoplasma
pneumoniae infection with thromboembolism and have a low threshold
for further evaluation when a patient is not improving as expected

